Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy.
Sanofi, Bridgewater, New Jersey.
Diabetes Obes Metab. 2019 Dec;21(12):2712-2717. doi: 10.1111/dom.13857. Epub 2019 Sep 3.
Diabetic dyslipidaemia is a major risk factor for accelerated atherosclerosis. Glycaemic treatments that improve dyslipidaemia may help reduce the burden of atherosclerosis. This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid profiles in patients with type 2 diabetes uncontrolled on basal insulin. Data from LixiLan-L were used to estimate changes in fasting lipid levels from baseline to week 30, overall and in patients stratified by achievement of glycaemic targets {2-hour postprandial glucose [≤10, >10 mmoL/L], fasting plasma glucose [≤6.1, >6.1 mmoL/L], HbA1c [≤7, >7% (≤53, >53 mmol/mol)]}. At week 30, median percentage change in triglycerides remained nearly unchanged (0.3% increase) with iGlarLixi versus a 6.5% increase with iGlar (P = 0.035; overall); similarly, trends towards better total and LDL cholesterol levels were observed with iGlarLixi versus iGlar. In patient subgroups achieving glycaemic targets, all lipid variables except for HDL cholesterol improved with iGlarLixi but not with iGlar. In summary, patients with type 2 diabetes uncontrolled on basal insulin showed improved fasting lipid profiles with iGlarLixi compared with iGlar, particularly when achieving glycaemic targets.
糖尿病血脂异常是加速动脉粥样硬化的主要危险因素。改善血脂异常的血糖治疗方法可能有助于减轻动脉粥样硬化的负担。本分析研究了 iGlarLixi [胰岛素 glargine U100（iGlar）和 lixisenatide]与 iGlar 相比对 2 型糖尿病患者基础胰岛素控制不佳的患者血脂谱的影响。使用 LixiLan-L 的数据来估计从基线到第 30 周空腹血脂水平的变化，总体和按血糖目标达标情况分层的患者 {2 小时餐后血糖[≤10，>10 mmol/L]，空腹血糖[≤6.1，>6.1 mmol/L]，HbA1c [≤7，>7%（≤53，>53 mmol/mol）]}。第 30 周时，iGlarLixi 组的甘油三酯中位数百分比变化几乎不变（增加 0.3%），而 iGlar 组增加 6.5%（P = 0.035；总体）；同样，iGlarLixi 组的总胆固醇和 LDL 胆固醇水平也呈现出改善的趋势。在血糖目标达标患者亚组中，除了 HDL 胆固醇外，所有脂质变量均随 iGlarLixi 改善，但随 iGlar 无改善。总之，与 iGlar 相比，基础胰岛素控制不佳的 2 型糖尿病患者空腹血脂谱得到改善，特别是在血糖目标达标时。
